2023
   A Coruña, Spain

I-01 Noha Abdelgawad Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis Wednesday 10:00-11:30

I-02 Chayan Acharya Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia Wednesday 10:00-11:30

I-05 Bram Agema Development of covariate-informed model pooling method to predict the correct starting dose Wednesday 10:00-11:30

I-06 Ana Alarcia Lacalle Population pharmacokinetic modelling and Monte Carlo simulation of piperacillin administered as extended infusion in critically ill patients Wednesday 10:00-11:30

I-07 Mounier Almett Population Pharmacokinetic Modelling of Twice Daily 50mg Dolutegravir in Children with Tuberculosis and HIV during Rifampicin Co-administration Wednesday 10:00-11:30

I-08 Stephen Amori apmx: an open-source R package for automated PK and PKPD dataset assembly Wednesday 10:00-11:30

I-09 Lena Appel Comparing the objective function value in NONMEM is valid for model selection when fixing THETA or OMEGA but not when fixing ETAs Wednesday 10:00-11:30

I-10 Arkadiusz Adamiszak Antibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis Wednesday 10:00-11:30

I-11 Marcus Baaz Model-based Prediction of Progression-Free Survival for Combination Therapies in Oncology Wednesday 10:00-11:30

I-12 Annabelle Ballesta Quantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors. Wednesday 10:00-11:30

I-13 Aurélie Barrail-Tran Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates Wednesday 10:00-11:30

I-14 Imke Bartelink Physiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer Wednesday 10:00-11:30

I-15 Carla Bastida Fernández Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections Wednesday 10:00-11:30

I-16 Maxime Beaulieu Simulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer Wednesday 10:00-11:30

I-17 Dinesh Bharadwaj Bedathuru Comparing Multiple Virtual Population Generation Approaches using as a base, a QSP Model of Rheumatoid Arthritis. Wednesday 10:00-11:30

I-18 Laura Ben Olivo Model-informed precision dosing web tool of busulfan for Brazilian pediatric patients Wednesday 10:00-11:30

I-19 Sandra Berja Population PK analysis of chloroquine in a humanized mouse model of P.falciparum malaria Wednesday 10:00-11:30

I-20 Elisa Borella Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients Wednesday 10:00-11:30

I-21 Muriel Boulton Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer Wednesday 10:00-11:30

I-22 Jose Miguel Calderin Miranda Pharmacokinetic analysis of pyrazinamide in a South African population with tuberculosis meningitis and HIV Wednesday 10:00-11:30

I-23 Aurore CARROT Prognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study Wednesday 10:00-11:30

I-24 Marc Cerou Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials Wednesday 10:00-11:30

I-25 Anan Chanruang Population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB Wednesday 10:00-11:30

I-26 Zhendong Chen Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain Wednesday 10:00-11:30

I-27 Mohammed Cherkaoui Rbati The transit compartment model: The truth behind n! Wednesday 10:00-11:30

I-28 Siak-Leng CHOI Applying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC) Wednesday 10:00-11:30

I-29 John Clements Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy Wednesday 10:00-11:30

I-30 Francois Combes Benchmarking Industrial Computing Environments - Pharmacometrics Study (BICEPS) Wednesday 10:00-11:30

I-31 Eulalie Courcelles Generation of a virtual population for a multi-strain model of natural and vaccinal immunization against influenza Wednesday 10:00-11:30

I-32 Ivan Demin Population pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis Wednesday 10:00-11:30

I-33 Anthea Deschamps Pharmacokinetics of cefotaxime in intensive care patients: exploration of the sources of variability with a population model Wednesday 10:00-11:30

I-34 Thomas Duflot Modelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ? Wednesday 10:00-11:30

I-35 Zrinka Duvnjak Performance evaluation of the full Automatic Model Development (AMD) tool when the true model is known Wednesday 10:00-11:30

I-36 Kevin Dykstra Population pharmacokinetics of vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for treatment of anemia associated with chronic kidney disease Wednesday 10:00-11:30

I-37 Omar Elkayal Model-based dose optimisation of intravenous posaconazole for treatment of patients with invasive aspergillosis in the intensive care unit Wednesday 10:00-11:30

I-38 Xiaoqing Fan Pharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia Wednesday 10:00-11:30

I-39 Aneeq Farooq In vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate. Wednesday 10:00-11:30

I-40 Fernandez Teruel Carlos Exposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant Wednesday 10:00-11:30

I-41 Matthew Fidler nlmixr2, rxode2 and NONMEM: interchangeable models using babelmixr2 and nonmem2rx Wednesday 10:00-11:30

I-42 Nuria Folguera-Blasco Studying Targeted Protein Degradation Using a Quantitative Systems Pharmacology (QSP) Approach for Proteolysis Targeting Chimeras (PROTACs) Wednesday 10:00-11:30

I-43 Wei Gao Population PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria Wednesday 10:00-11:30

I-44 Glenn Gauderat Mechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data Wednesday 10:00-11:30

I-45 Kamunkhwala Gausi Bactericidal activity of pretomanid against drug-sensitive tuberculosis in the presence of rifamycins Wednesday 10:00-11:30

I-46 Eva Germovsek A semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus Wednesday 10:00-11:30

I-47 Asina Gijasi Development of an R Shiny application to aid pre-clinical development of immune-oncology compounds at Genmab Wednesday 10:00-11:30

I-48 Daniel Glazar A simulation-based sample size analysis of a joint model of longitudinal and survival data for patients with glioma Wednesday 10:00-11:30

I-49 Xiaohua Gong Pharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements Wednesday 10:00-11:30

I-50 Sebastiaan Goulooze Conditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making Wednesday 10:00-11:30

I-51 Mélanie Guhl Uncertainty computation at finite distance in nonlinear mixed effects models - a new method evaluated on simulations and applied to the evolution of clinical status of patients hospitalised for COVID-19 Wednesday 10:00-11:30

I-52 Jinju Guk Integration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling. Wednesday 10:00-11:30

I-53 Michael Hackl Visualising and integrating automated model development within a validated environment Wednesday 10:00-11:30

I-54 Ibtihel Hammami Application of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy Wednesday 10:00-11:30

I-55 Irene Hernández-Lozano Translational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections Wednesday 10:00-11:30

I-56 Jennifer Hibma Population Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma Wednesday 10:00-11:30

I-57 Nick Holford A Physiological Approach to Renal Clearance - from Premature Neonates to Adults Wednesday 10:00-11:30

I-58 Miao-Chan Huang Population pharmacokinetic analysis of amoxicillin in postpartum Göttingen Minipig plasma and milk: a contribution from the ConcePTION project Wednesday 10:00-11:30

I-59 Itziar Irurzun Arana Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer Wednesday 10:00-11:30

I-60 Hyeseon Jeon Construction of model-based PK-PD software platform using R package considering compatibility of nlme structured model Wednesday 10:00-11:30

I-61 Jihyun Jeon Quantitative approaches of time-varying weight gain effects of antipsychotic drugs for Schizophrenia by model based meta-analysis. Wednesday 10:00-11:30

I-62 Felix Jost Model-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design Wednesday 10:00-11:30

I-63 Piotr Juszczak Modelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older Wednesday 10:00-11:30

I-64 Allan Kengo Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Wednesday 10:00-11:30

I-65 Charlotte Kern Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial Wednesday 10:00-11:30

I-66 Dohoon Keum Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients Wednesday 10:00-11:30

I-67 Huub Jan Kleijn Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers Wednesday 10:00-11:30

I-68 Fenja Klima Separating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data Wednesday 10:00-11:30

I-69 Simon Koele Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis Wednesday 10:00-11:30

I-70 Sjoerd Koopman Bayesian forecasting of recombinant factor IX-Fc fusion protein concentrate dosing in haemophilia B patients: Comparison of the performance of two population pharmacokinetic models Wednesday 10:00-11:30

I-71 Hongjae Lee Population pharmacokinetics of FM101 in healthy volunteers and long-term safety prediction: phase 1 study Wednesday 10:00-11:30

I-72 Yu-wei Lin Population pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg Wednesday 10:00-11:30

I-73 Ioannis Loisios-Konstantinidis Combining physiologically based pharmacokinetic modeling and simulations and allometry to inform the starting dose of asciminib in pediatric patients Wednesday 10:00-11:30

I-74 Anaëlle Monfort A population pharmacokinetic model for sertraline in depressive patients during the perinatal period: prediction of infant drug exposure through placenta and human milk Wednesday 10:00-11:30

I-75 Michael Monine Prediction and validation of antisense oligonucleotide distribution in human central nervous system Wednesday 10:00-11:30

I-76 Nele Mueller-Plock Population pharmacokinetic - pharmacodynamic analysis of dopamine D2 receptor occupancy following doses of TV 46000, an extended release suspension of risperidone for treatment of schizophrenia Wednesday 10:00-11:30

I-77 Paraskevi Papakyriakopoulou Donepezil brain and blood pharmacokinetic modeling after nasal film and oral solution administration in mice Wednesday 10:00-11:30

I-78 Juan Jose Perez Ruixo Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis Wednesday 10:00-11:30

I-79 Belén Pérez Solans Pharmacokinetic analysis across studies to drive knowledge-integration: optimal dose finding of rifampicin for the treatment of drug-susceptible tuberculosis in children Wednesday 10:00-11:30

I-80 Soumya Perinparajah Modelling the pharmacodynamics of rituximab biosimilar in children with rheumatological conditions Wednesday 10:00-11:30

I-81 Anne Ravix Dosing optimization of amoxicillin in children treated for Lyme disease Wednesday 10:00-11:30

I-82 Leyanis Rodriguez Vera Showcasing the potential of PBPK modeling to inform drug-drug interactions specific recommendations for pediatric labeling: omeprazol case example Wednesday 10:00-11:30

I-83 Kyong Kuk Ryu Population pharmacokinetics of ticagrelor and active metabolite during veno-arterial extracorporeal membrane oxygenation Wednesday 10:00-11:30

I-84 Stephan Schaller Using PBPK Modeling to support an adaptive “First-in-Pediatric” trial design of Sonlicromanol for the treatment of Primary Mitochondrial Disease Wednesday 10:00-11:30

I-85 Maja Skataric Dabrafenib and Trametinib dose optimization in 6-17 year old tumor agnostic patients based on established efficacy surrogate targets in adults Wednesday 10:00-11:30

I-86 Melina Steichert Enalapril orodispersible minitablets for pediatric heart failure - a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials Wednesday 10:00-11:30

I-87 Mita Thapar Population pharmacokinetic and exposure-response analysis for ambrisentan for the treatment of pulmonary arterial hypertension in paediatric subjects aged 8 to less than 18 years. Wednesday 10:00-11:30

I-88 Elena Tosca Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach Wednesday 10:00-11:30

I-89 Mira Tout A translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues Wednesday 10:00-11:30

I-90 Lufina Tsirizani Population pharmacokinetics of ritonavir-boosted darunavir in children aged 3 to 15 years in the CHAPAS 4 trial living with HIV in Africa. Wednesday 10:00-11:30

I-91 Lisa van der Heijden Quantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours Wednesday 10:00-11:30

I-92 Sebastian Wicha In vitro pharmacodynamic drug-drug interaction and translational evaluation of cabamiquine and pyronaridine as new antimalarial combination using P.falciparum field isolates Wednesday 10:00-11:30

I-93 Marie Wijk Analysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis Wednesday 10:00-11:30

I-94 Venkata Yellepeddi Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients Wednesday 10:00-11:30

I-95 Anyue Yin Population pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma Wednesday 10:00-11:30

I-96 Seok Kyue Yoon Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer Wednesday 10:00-11:30

I-97 Yu-Jou Lin A pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment Wednesday 10:00-11:30

I-98 Renwei Zhang A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC Wednesday 10:00-11:30